Skip to content

REFERENCE FILE

Tesamorelin

Examine the reference details alongside the questions and dated sources.

Reference details

Status as of

Regulatory category
Approved product
Evidence category
Randomized evidence
Mechanism
Stimulates growth-hormone release.
Evidence
A randomized trial measured visceral fat.
Limitations
Not for weight management.
Safety
Active malignancy is a contraindication.
Formulation and route
Specified subcutaneous formulation.
Approval scope
Egrifta WR addresses excess abdominal fat in adults with HIV-associated lipodystrophy.

READING NOTES

Questions for a closer look

Inspect a percentage in a tesamorelin discussion by asking what one counted item would look like. Would an entry represent a person, an episode, a visit or something else? Find the answer in the table heading and notes, then check whether the total beneath the percentage uses that same unit. Imagine a record containing repeated entries and ask how the stated counting rule would handle it. Avoid performing a conversion until the required relationship between units is documented. Your finished annotation should let another reader identify exactly what was counted, including how repetition enters the calculation.

Questions to investigate

  1. What would one counted item represent under the table's stated definition?
  2. How would repeated entries from the same record enter the calculation?
  3. Does the total use the same unit as the items being counted?

Sources for this file

  1. EGRIFTA WRNLM · Checked
  2. Falutz trialPubMed · Checked

MED CONSUMER WATCH · RESEARCH

Read the evidence behind the question.

Browse reference files or follow a study analysis from its question to its limitations.